C4 Therapeutics Clinical Trial Data
C4 Therapeutics presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and preliminary Phase 1b data for cemsidomide combined with elranatamab at the 23rd International Myeloma Society Annual Meeting. The data demonstrated that cemsidomide drives T-cell activation and prevents T-cell exhaustion, supporting its potential as a combination partner for immune-based therapies in relapsed/refractory multiple myeloma. Additionally, the 75 µg dose level in the Phase 1b trial was declared safe, allowing the study to advance to dose expansion and escalation cohorts.